McKesson Defends Right To $7M Of Disputed Orexigen Funds

By Vince Sullivan (September 4, 2018, 8:56 PM EDT) -- Drug distributor McKesson Corp. and a subsidiary reiterated their belief that they are entitled to $7 million in disputed funds being held by debtor Orexigen Therapeutics Inc. in its Delaware Chapter 11 case, arguing that the basis for opposition to release of the money put forth by lenders and the debtor doesn't comport with the law as written....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!